Rib-X Pharmaceuticals, Inc., a New Haven, CT-based company that develops broad spectrum antibiotics, has raised $20m in funding.
The financing was led by existing investor Warburg Pincus LLC.
The company intends to use the funds to support ongoing development of its broad spectrum antibiotics pipeline, including late-stage clinical development of delafloxacin, which is expected to enter a Phase 2b study in early 2011.
Delafloxacin is a hospital focused novel fluoroquinolone antibiotic that offers both IV and oral versatility in the treatment of resistant infections.
Rib-X’ pipeline also includes Radezolid, an oxazolidinone antibiotic designed to have a broader spectrum of coverage and increased activity against Gram-positive organisms as compared to other oxazolidinones, as well as Rχ-04, a broad spectrum antibiotic that is active against serious, rapidly emerging multi-drug resistant bacteria, including Gram-negative bacteria.
The company is led by President and CEO Mark Leuchtenberger.